Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
3 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Alto Neuroscience Inc.’s names, not what it holds today.
Patents granted
3
3 utility, 1976 to Dec 31, 2025
Granted in 2025
3
in the last year the record reads
Applications published
21
9 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
Medical technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Alto Neuroscience, Inc. its own name
named as the applicant on its applications, in US
21 publishedAlto Neuroscience, Inc. its own name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Feb 25, 2025 | 12,233,059 | Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent | Pharmaceuticals | Alto Neuroscience, Inc. |
| Feb 18, 2025 | 12,226,375 | Method of treatment and selection of patients benefiting from agomelatine based on EEG measurements | Pharmaceuticals | Alto Neuroscience, Inc. |
| Jan 28, 2025 | 12,208,096 | Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent | Medical technology | Alto Neuroscience, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jun 5, 2025 | 2025/0177387 | EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | Pharmaceuticals | Alto Neuroscience, Inc. |
| Jun 5, 2025 | 2025/0177386 | METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | Pharmaceuticals | Alto Neuroscience, Inc. |
| Jun 5, 2025 | 2025/0177331 | METHOD OF TREATMENT AND SELECTION OF PATIENTS BENEFITING FROM AGOMELATINE BASED ON EEG MEASUREMENTS | Pharmaceuticals | Alto Neuroscience, Inc. |
| May 8, 2025 | 2025/0144092 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | Pharmaceuticals | Alto Neuroscience, Inc. |
| Apr 17, 2025 | 2025/0120957 | TREATMENT OF NEUROPSYCHIATRIC DISORDERS WITH TILIVAPRAM | Pharmaceuticals | Alto Neuroscience, Inc. |
| Feb 13, 2025 | 2025/0050053 | METHOD OF TREATMENT AND SELECTION OF PATIENTS BENEFITING FROM AGOMELATINE BASED ON EEG MEASUREMENTS | Pharmaceuticals | Alto Neuroscience, Inc. |
| Feb 13, 2025 | 2025/0049739 | METHOD OF TREATMENT AND SELECTION OF PATIENTS BENEFITING FROM AGOMELATINE BASED ON EEG MEASUREMENTS | Pharmaceuticals | Alto Neuroscience, Inc. · patent 12,226,375 granted from it |
| Feb 13, 2025 | 2025/0049738 | METHOD OF TREATMENT AND SELECTION OF PATIENTS BENEFITING FROM AGOMELATINE BASED ON EEG MEASUREMENTS | Pharmaceuticals | Alto Neuroscience, Inc. |
| Jan 9, 2025 | 2025/0009738 | EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | Medical technology | Alto Neuroscience, Inc. |
| Oct 17, 2024 | 2024/0342165 | METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | Pharmaceuticals | Alto Neuroscience, Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 15 · Medical technology 3.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.